Does the media refer more to CLPT or BLFS?

In the previous week, ClearPoint Neuro had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for ClearPoint Neuro and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.33 beat ClearPoint Neuro's score of 0.14 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioLife Solutions 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CLPT or INSP?

In the previous week, Inspire Medical Systems had 21 more articles in the media than ClearPoint Neuro. MarketBeat recorded 31 mentions for Inspire Medical Systems and 10 mentions for ClearPoint Neuro. Inspire Medical Systems' average media sentiment score of 1.31 beat ClearPoint Neuro's score of 0.14 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Inspire Medical Systems 21 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CDRE or CLPT?

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadre $610.31M 2.31 $44.14M $0.85 38.80 ClearPoint Neuro $36.97M 11.72 -$25.54M -$1.18 N/A

Is CDRE or CLPT more profitable?

Cadre has a net margin of 5.26% compared to ClearPoint Neuro's net margin of -81.76%. Cadre's return on equity of 12.02% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Cadre 5.26% 12.02% 4.80% ClearPoint Neuro -81.76% -188.09% -40.88%

Does the media prefer CDRE or CLPT?

In the previous week, Cadre had 12 more articles in the media than ClearPoint Neuro. MarketBeat recorded 22 mentions for Cadre and 10 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.80 beat ClearPoint Neuro's score of 0.14 indicating that Cadre is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 9 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CLPT or KMTS?

In the previous week, Kestra Medical Technologies had 35 more articles in the media than ClearPoint Neuro. MarketBeat recorded 45 mentions for Kestra Medical Technologies and 10 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.14 beat Kestra Medical Technologies' score of 0.10 indicating that ClearPoint Neuro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kestra Medical Technologies 22 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CNMD or CLPT?

CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 1.07 $47.06M $1.85 26.48 ClearPoint Neuro $36.97M 11.72 -$25.54M -$1.18 N/A

Does the media favor CNMD or CLPT?

In the previous week, ClearPoint Neuro had 6 more articles in the media than CONMED. MarketBeat recorded 10 mentions for ClearPoint Neuro and 4 mentions for CONMED. CONMED's average media sentiment score of 1.39 beat ClearPoint Neuro's score of 0.14 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

ClearPoint Neuro (CLPT) Competitors

$14.21 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$14.34 +0.13 (+0.88%)

As of 08:19 AM Eastern

Compare

CLPT vs. BLFS, INSP, CDRE, KMTS, and CNMD

Should you buy ClearPoint Neuro stock or one of its competitors? MarketBeat compares ClearPoint Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ClearPoint Neuro include BioLife Solutions (BLFS), Inspire Medical Systems (INSP), Cadre (CDRE), Kestra Medical Technologies (KMTS), and CONMED (CNMD).

How does ClearPoint Neuro compare to BioLife Solutions?

ClearPoint Neuro (NASDAQ:CLPT) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 80.62%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 9.48%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ClearPoint Neuro had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for ClearPoint Neuro and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.33 beat ClearPoint Neuro's score of 0.14 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioLife Solutions	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to ClearPoint Neuro's net margin of -81.76%. BioLife Solutions' return on equity of 2.70% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
BioLife Solutions	53.29%	2.70%	2.49%

BioLife Solutions has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	11.72	-$25.54M	-$1.18	N/A
BioLife Solutions	$106.69M	15.87	-$4.59M	$1.16	29.88

ClearPoint Neuro has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Summary

BioLife Solutions beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Inspire Medical Systems?

ClearPoint Neuro (NASDAQ:CLPT) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Inspire Medical Systems has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	11.72	-$25.54M	-$1.18	N/A
Inspire Medical Systems	$911.98M	1.91	$145.42M	$4.62	13.01

ClearPoint Neuro has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 80.62%. Inspire Medical Systems has a consensus target price of $68.00, suggesting a potential upside of 13.10%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inspire Medical Systems	3 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.10

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Inspire Medical Systems had 21 more articles in the media than ClearPoint Neuro. MarketBeat recorded 31 mentions for Inspire Medical Systems and 10 mentions for ClearPoint Neuro. Inspire Medical Systems' average media sentiment score of 1.31 beat ClearPoint Neuro's score of 0.14 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inspire Medical Systems	21 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspire Medical Systems has a net margin of 15.03% compared to ClearPoint Neuro's net margin of -81.76%. Inspire Medical Systems' return on equity of 8.64% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Inspire Medical Systems	15.03%	8.64%	7.45%

Summary

Inspire Medical Systems beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Cadre?

Cadre (NYSE:CDRE) and ClearPoint Neuro (NASDAQ:CLPT) are related small-cap companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

44.0% of Cadre shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 30.1% of Cadre shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cadre had 12 more articles in the media than ClearPoint Neuro. MarketBeat recorded 22 mentions for Cadre and 10 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.80 beat ClearPoint Neuro's score of 0.14 indicating that Cadre is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	9 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cadre currently has a consensus target price of $41.40, suggesting a potential upside of 25.52%. ClearPoint Neuro has a consensus target price of $25.67, suggesting a potential upside of 80.62%. Given ClearPoint Neuro's higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cadre has a net margin of 5.26% compared to ClearPoint Neuro's net margin of -81.76%. Cadre's return on equity of 12.02% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.26%	12.02%	4.80%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

Cadre has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.31	$44.14M	$0.85	38.80
ClearPoint Neuro	$36.97M	11.72	-$25.54M	-$1.18	N/A

Summary

Cadre beats ClearPoint Neuro on 15 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Kestra Medical Technologies?

ClearPoint Neuro (NASDAQ:CLPT) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

ClearPoint Neuro has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

ClearPoint Neuro has higher earnings, but lower revenue than Kestra Medical Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	11.72	-$25.54M	-$1.18	N/A
Kestra Medical Technologies	$95.13M	16.26	-$131.61M	-$2.42	N/A

In the previous week, Kestra Medical Technologies had 35 more articles in the media than ClearPoint Neuro. MarketBeat recorded 45 mentions for Kestra Medical Technologies and 10 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.14 beat Kestra Medical Technologies' score of 0.10 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kestra Medical Technologies	22 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro currently has a consensus target price of $25.67, indicating a potential upside of 80.62%. Kestra Medical Technologies has a consensus target price of $28.14, indicating a potential upside of 6.60%. Given ClearPoint Neuro's higher possible upside, equities analysts plainly believe ClearPoint Neuro is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ClearPoint Neuro has a net margin of -81.76% compared to Kestra Medical Technologies' net margin of -138.35%. Kestra Medical Technologies' return on equity of -57.38% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%

Summary

ClearPoint Neuro beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to CONMED?

CONMED (NYSE:CNMD) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

CONMED presently has a consensus price target of $41.40, suggesting a potential downside of 15.50%. ClearPoint Neuro has a consensus price target of $25.67, suggesting a potential upside of 80.62%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ClearPoint Neuro had 6 more articles in the media than CONMED. MarketBeat recorded 10 mentions for ClearPoint Neuro and 4 mentions for CONMED. CONMED's average media sentiment score of 1.39 beat ClearPoint Neuro's score of 0.14 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CONMED has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

CONMED has a net margin of 4.12% compared to ClearPoint Neuro's net margin of -81.76%. CONMED's return on equity of 14.31% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	1.07	$47.06M	$1.85	26.48
ClearPoint Neuro	$36.97M	11.72	-$25.54M	-$1.18	N/A

30.1% of ClearPoint Neuro shares are held by institutional investors. 0.3% of CONMED shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CONMED and ClearPoint Neuro tied by winning 8 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$433.41M	$5.76B	$7.00B	$12.99B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-12.04	24.26	270.62	25.05
Price / Sales	11.72	68.41	659.52	107.93
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	14.35	6.11	11.20	6.43
Net Income	-$25.54M	$149.01M	$3.45B	$348.10M
7 Day Performance	-7.61%	2.35%	3.40%	2.66%
1 Month Performance	-18.80%	0.63%	-0.72%	-0.85%
1 Year Performance	31.33%	4.90%	77.41%	23.96%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.6651 of 5 stars	$14.21 flat	$25.67 +80.6%	+31.3%	$433.41M	$36.97M	N/A	110	Earnings Report Analyst Downgrade
BLFS BioLife Solutions	3.5349 of 5 stars	$32.89 +10.4%	$31.38 -4.6%	+52.8%	$1.60B	$96.21M	N/A	440	Positive News Earnings Report
INSP Inspire Medical Systems	4.109 of 5 stars	$50.08 -1.7%	$73.28 +46.3%	-24.1%	$1.44B	$915.25M	11.13	1,333	Positive News Earnings Report Gap Down
CDRE Cadre	4.1566 of 5 stars	$33.58 +2.4%	$39.80 +18.5%	+8.1%	$1.44B	$635.63M	37.79	2,533	Earnings Report Analyst Forecast
KMTS Kestra Medical Technologies	1.5035 of 5 stars	$23.78 +4.2%	$27.83 +17.1%	+81.8%	$1.39B	$95.13M	N/A	300	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. BLFS, INSP, CDRE, KMTS, and CNMD

How does ClearPoint Neuro compare to BioLife Solutions?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Summary

How does ClearPoint Neuro compare to Cadre?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Summary

How does ClearPoint Neuro compare to CONMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. BLFS, INSP, CDRE, KMTS, and CNMD

How does ClearPoint Neuro compare to BioLife Solutions?

Do analysts recommend CLPT or BLFS?

Do insiders & institutionals hold more shares of CLPT or BLFS?

Does the media refer more to CLPT or BLFS?

Is CLPT or BLFS more profitable?

Which has preferable earnings and valuation, CLPT or BLFS?

Which has more volatility & risk, CLPT or BLFS?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Which has stronger valuation and earnings, CLPT or INSP?

Which has more risk and volatility, CLPT or INSP?

Do analysts rate CLPT or INSP?

Do insiders and institutionals believe in CLPT or INSP?

Does the media refer more to CLPT or INSP?

Is CLPT or INSP more profitable?

Summary

How does ClearPoint Neuro compare to Cadre?

Do insiders and institutionals hold more shares of CDRE or CLPT?

Does the media prefer CDRE or CLPT?

Do analysts prefer CDRE or CLPT?

Is CDRE or CLPT more profitable?

Which has more volatility and risk, CDRE or CLPT?

Which has preferable earnings and valuation, CDRE or CLPT?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Which has more volatility and risk, CLPT or KMTS?

Which has stronger earnings & valuation, CLPT or KMTS?

Does the media prefer CLPT or KMTS?

Do analysts recommend CLPT or KMTS?

Do institutionals and insiders believe in CLPT or KMTS?

Is CLPT or KMTS more profitable?

Summary

How does ClearPoint Neuro compare to CONMED?

Do analysts prefer CNMD or CLPT?

Does the media favor CNMD or CLPT?

Which has more volatility and risk, CNMD or CLPT?

Is CNMD or CLPT more profitable?

Which has preferable earnings and valuation, CNMD or CLPT?

Do institutionals & insiders hold more shares of CNMD or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools